PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11443053-8 2001 In contrast, two NADPH binding site deletion mutants of eNOS that lack oxidase activity had no effect on p42/44 MAPK. NADP 17-22 nitric oxide synthase 3 Homo sapiens 56-60 12756290-1 2003 The enzyme endothelial nitric oxide synthase (eNOS) catalyzes the conversion of arginine, oxygen and NADPH to NO and citrulline. NADP 101-106 nitric oxide synthase 3 Homo sapiens 11-44 12756290-1 2003 The enzyme endothelial nitric oxide synthase (eNOS) catalyzes the conversion of arginine, oxygen and NADPH to NO and citrulline. NADP 101-106 nitric oxide synthase 3 Homo sapiens 46-50 12519764-7 2003 HSP90 also significantly increased the rate of NADPH-dependent cytochrome c reduction by eNOS at both low and high Ca(2+) concentrations. NADP 47-52 nitric oxide synthase 3 Homo sapiens 89-93 11443071-9 2001 Rather, CDNB treatment impaired eNOS catalytic activity in intact PAECs, and this effect was reversed by excess NADPH in isolated purified eNOS assays. NADP 112-117 nitric oxide synthase 3 Homo sapiens 139-143 10747895-8 2000 In contrast, cotransfection of superoxide dismutase with eNOS prevented TNFalpha up-regulation, as did partial deletion of the eNOS NADPH binding site, a mutation associated with loss of O(2) production. NADP 132-137 nitric oxide synthase 3 Homo sapiens 57-61 11382920-11 2001 We propose that hypoxia, by altering cellular metabolism, leads to an increase in the cellular NAD(P)H/NAD(P) ratio which favors enhanced eNOS expression by redox-sensitive AP-1 mediated transcriptional control. NADP 95-101 nitric oxide synthase 3 Homo sapiens 138-142 10747895-8 2000 In contrast, cotransfection of superoxide dismutase with eNOS prevented TNFalpha up-regulation, as did partial deletion of the eNOS NADPH binding site, a mutation associated with loss of O(2) production. NADP 132-137 nitric oxide synthase 3 Homo sapiens 127-131 10653901-1 2000 OBJECTIVE: Endothelial nitric oxide synthase (ecNOS) catalyzes the NADPH and O(2) to nitric oxide(NO). NADP 67-72 nitric oxide synthase 3 Homo sapiens 11-44 10653901-1 2000 OBJECTIVE: Endothelial nitric oxide synthase (ecNOS) catalyzes the NADPH and O(2) to nitric oxide(NO). NADP 67-72 nitric oxide synthase 3 Homo sapiens 46-51 9042951-3 1997 We show, using the phosphorylated spin trap 5-diethoxyphosphoryl-5-methyl-1-pyrroline N-oxide (DEPMPO), that lucigenin stimulates NADPH-dependent superoxide production by endothelial nitric oxide synthase (eNOS). NADP 130-135 nitric oxide synthase 3 Homo sapiens 171-204 9333325-7 1997 Adriamycin binds to eNOS with a Km of approximately 5 microM, as calculated from both eNOS-dependent NADPH consumption and superoxide generation. NADP 101-106 nitric oxide synthase 3 Homo sapiens 20-24 9333325-7 1997 Adriamycin binds to eNOS with a Km of approximately 5 microM, as calculated from both eNOS-dependent NADPH consumption and superoxide generation. NADP 101-106 nitric oxide synthase 3 Homo sapiens 86-90 9149402-7 1997 The deduced amino acid sequence of porcine ecNOS cDNA, containing binding sites for NADPH, flavin adenine dinucleotide and bound flavin mononucleotide, shows 94% identity to human ecNOS. NADP 84-89 nitric oxide synthase 3 Homo sapiens 43-48 8806629-7 1996 These results indicate that Cys-1048 and Cys-1114 residues in the NADPH binding site of the reductase domain are critical for human ecNOS activity. NADP 66-71 nitric oxide synthase 3 Homo sapiens 132-137 8806629-8 1996 The lack of utilization of NADPH in L-arginine metabolism and in cytochrome c reduction suggests that these active site cysteine residues may be responsible for binding of NADPH and/or for electron transfer in human ecNOS. NADP 172-177 nitric oxide synthase 3 Homo sapiens 216-221 23648561-4 2013 Rosuvastatin maintain the balance between oxidant generation and oxidant scavenging by reducing NADPH (nicotinamide adenine dinucleotide phosphate)-dependent production of reactive oxygen species, suppressing endothelial nitric oxide synthase (eNOS) uncoupling, inducing and upregulating antioxidant defense mechanism. NADP 96-101 nitric oxide synthase 3 Homo sapiens 209-242 28108596-2 2017 This NADP(H) depletion was shown to limit the production of nitric oxide by endothelial nitric oxide synthase (eNOS), which requires NADPH for nitric oxide production, resulting in greatly altered endothelial function. NADP 5-12 nitric oxide synthase 3 Homo sapiens 76-109 28108596-2 2017 This NADP(H) depletion was shown to limit the production of nitric oxide by endothelial nitric oxide synthase (eNOS), which requires NADPH for nitric oxide production, resulting in greatly altered endothelial function. NADP 133-138 nitric oxide synthase 3 Homo sapiens 76-109 7536383-4 1995 The inhibition of cNOS was specific, since to some degree NADPH (0.5-4 mM) and more effectively L-arginine (0.1-1 mM), but not D-arginine, reversed the inhibition. NADP 58-63 nitric oxide synthase 3 Homo sapiens 18-22 21724868-2 2011 In the absence of the requisite eNOS cofactor tetrahydrobiopterin (BH(4)), NADPH oxidation is uncoupled from NO generation, leading to the production of superoxide. NADP 75-80 nitric oxide synthase 3 Homo sapiens 32-36 21198553-3 2011 Similar to all NOS isoforms, functional eNOS transfers electrons from nicotinamide adenine dinucleotide phosphate (NADPH), via the flavins flavin adenine dinucleotide and flavin mononucleotide in the carboxy-terminal reductase domain, to the heme in the amino-terminal oxygenase domain. NADP 70-113 nitric oxide synthase 3 Homo sapiens 40-44 21198553-3 2011 Similar to all NOS isoforms, functional eNOS transfers electrons from nicotinamide adenine dinucleotide phosphate (NADPH), via the flavins flavin adenine dinucleotide and flavin mononucleotide in the carboxy-terminal reductase domain, to the heme in the amino-terminal oxygenase domain. NADP 115-120 nitric oxide synthase 3 Homo sapiens 40-44 21179168-2 2010 In the presence of Ca(2+)/calmodulin, eNOS produces NO, endothelial-derived relaxing factor, from l-arginine (l-Arg) by means of electron transfer from NADPH through a flavin containing reductase domain to oxygen bound at the haem of an oxygenase domain, which also contains binding sites for tetrahydrobiopterin (BH(4)) and l-Arg. NADP 152-157 nitric oxide synthase 3 Homo sapiens 38-42 17263536-3 2007 Specific binding of the nanotrigger to the reductase domain of the endothelial nitric oxide synthase (eNOSred) was demonstrated by competition between NADPH and the nanotrigger on the reduction of eNOSred flavin. NADP 151-156 nitric oxide synthase 3 Homo sapiens 67-100 22929836-7 2012 Nitric oxide (NO) synthase which comes in three isoforms, as inducible-, neuronal- and endothelial-NOS, or iNOS, nNOS or eNOS, respectively, catalyzes the conversion of L- arginine to L-citrulline, using NADPH to produce NO. NADP 204-209 nitric oxide synthase 3 Homo sapiens 121-125 17698846-4 2007 In the presence of both L-arginine and tetrahydrobiopterin, eNOS is highly coupled (>90%), and the measured stoichiometry of O(2)/NADPH is very close to the theoretical value. NADP 133-138 nitric oxide synthase 3 Homo sapiens 60-64 17610838-1 2007 The object of this study was to clarify the mechanism of electron transfer in the human endothelial nitric oxide synthase (eNOS) reductase domain using recombinant eNOS reductase domains; the FAD/NADPH domain containing FAD- and NADPH-binding sites and the FAD/FMN domain containing FAD/NADPH-, FMN-, and a calmodulin-binding sites. NADP 196-201 nitric oxide synthase 3 Homo sapiens 88-121 17610838-1 2007 The object of this study was to clarify the mechanism of electron transfer in the human endothelial nitric oxide synthase (eNOS) reductase domain using recombinant eNOS reductase domains; the FAD/NADPH domain containing FAD- and NADPH-binding sites and the FAD/FMN domain containing FAD/NADPH-, FMN-, and a calmodulin-binding sites. NADP 229-234 nitric oxide synthase 3 Homo sapiens 88-121 17610838-1 2007 The object of this study was to clarify the mechanism of electron transfer in the human endothelial nitric oxide synthase (eNOS) reductase domain using recombinant eNOS reductase domains; the FAD/NADPH domain containing FAD- and NADPH-binding sites and the FAD/FMN domain containing FAD/NADPH-, FMN-, and a calmodulin-binding sites. NADP 229-234 nitric oxide synthase 3 Homo sapiens 88-121